AstraZeneca drives biomarker testing with a string of efforts—and a new leader

While the list of biomarker-targeted drugs keeps on growing, diagnostic testing is still behind. AstraZeneca wants to change that—and it's launched a handful of awareness efforts to make doctors and patients aware of their options.